Immune Presentation and Regulation
Publications
Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study).
5. Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Menéndez O, Ayats J, Castro C, García-Rodríguez J, Goterris-Bonet L, Ibáñez-Martínez E, Linares-Sicilia MJ, Martin-Gomez MT, Martín-Mazuelos E, Pelaez T, Peman J, Rezusta A, Rojo S, Tejero R, Anza DV, Viñuelas J, Zapico MS, Cuenca-Estrella M; the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI. Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study). Antimicrob Agents Chemother. 2018 Aug 27;62(9).
PUBMED DOIEvaluation of Bronchoalveolar Lavage Fluid Cytokines as Biomarkers for Invasive Pulmonary Aspergillosis in At-Risk Patients
6. Gonçalves SM, Lagrou K, Rodrigues CS, Campos CF, Bernal-Martínez L, Rodrigues F, Silvestre R, Alcazar-Fuoli L, Maertens JA, Cunha C, Carvalho A. Evaluation of Bronchoalveolar Lavage Fluid Cytokines as Biomarkers for Invasive Pulmonary Aspergillosis in At-Risk Patients. Front Microbiol. 2017 Nov 29;8:2362.
PUBMED DOIPolymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium
7. Lupiañez CB, Canet LM, Carvalho A, Alcazar-Fuoli L, Springer J, Lackner M, Segura-Catena J, Comino A, Olmedo C, Ríos R, Fernández-Montoya A, Cuenca-Estrella M, Solano C, López-Nevot MÁ, Cunha C, Oliveira-Coelho A, Villaescusa T, Fianchi L, Aguado JM, Pagano L, López-Fernández E, Potenza L, Luppi M, Lass-Flörl C, Loeffler J, Einsele H, Vazquez L; PCRAGA Study Group, Jurado M, Sainz J. Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium. Infect Immun. 2015 Dec 14;84(3):643-57.
PUBMED DOICell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host.
9. Mesa-Arango AC, Rueda C, Román E, Quintin J, Terrón MC, Luque D, Netea MG, Pla J and Zaragoza O. Cell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host. Antimicrob. Agents Chemother. 2016. 60(4):2326-35.
PUBMED DOIThe role of respiratory viruses in children with humoral immunodeficiency on immunoglobulin replacement therapy
Benavides-Nieto M, Méndez-Echevarría A, Del Rosal T, García-García ML, Casas I, Pozo F, de la Serna O, Lopez-Granados E, Rodriguez-Pena R, Calvo C. The role of respiratory viruses in children with humoral immunodeficiency on immunoglobulin replacement therapy. Pediatr Pulmonol. 2019 Feb;54(2):194-199. Indice Impacto: 3,157. Revista en Q1.
PUBMED DOISeasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016.
Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P; European Influenza Surveillance Network. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill. 2018 Feb;23(5). Indice Impacto: 5,983. Revista en Decil 1
PUBMED DOIHuman Metapneumovirus infections in hospitalized children and comparison with other respiratory viruses in 2005-2014 prospective study.
García-García ML, Calvo C, Rey C, Díaz B, Molinero MD, Pozo F, Casas I. Human Metapneumovirus infections in hospitalized children and comparison with other respiratory viruses in 2005-2014 prospective study. PLoS One. 2017 Mar 16;12(3):e0173504. doi: 10.1371/journal.pone.0173504. eCollection 2017. Indice Impacto: 2,766. Revista en Q1.
PUBMED DOIRespiratory Infections by Enterovirus D68 in Outpatients and Inpatients Spanish Children
Calvo C, Cuevas MT, Pozo F, García-García ML, Molinero M, Calderón A, Gonzalez-Esguevillas M, Pérez-Sautu U, Casas I. Respiratory Infections by Enterovirus D68 in Outpatients and Inpatients Spanish Children. Pediatr Infect Dis J. 2016 Jan;35(1):45-9.
PUBMED DOIClinical and Virologic Characteristics of Early and Moderate Preterm Infants Readmitted with Viral Respiratory Infections.
García-Garcia ML, González-Carrasco E, Quevedo S, Muñoz C, Sánchez-Escudero V, Pozo F, Casas I, Calvo C. Clinical and Virologic Characteristics of Early and Moderate Preterm Infants Readmitted with Viral Respiratory Infections. Pediatr Infect Dis J. 2015 Jul;34(7):693-9. Indice Impacto: 2,587. Revista en Q1
PUBMED DOIEight Year Prospective Study of Adenoviruses Infections in Hospitalized Children. Comparison with Other Respiratory Viruses.
Calvo C, García-García ML, Sanchez-Dehesa R, Román C, Tabares A, Pozo F, Casas I. Eight Year Prospective Study of Adenoviruses Infections in Hospitalized Children. Comparison with Other Respiratory Viruses. PLoS One. 2015 Jul 6;10(7):e0132162. eCollection 2015. Indice Impacto: 3,057. Revista en Q1
PUBMED DOIInfluenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study
Jiménez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, García-Cenoz M, Castilla J, Sancho R, Etxebarriarteun-Aranzabal L, Quinones C, Martínez E, Vega T, Garcia A, Giménez J, Vanrell JM, Castrillejo D, Larrauri A, on behalf of the Spanish Influenza Sentinel Surveillance System (SISS). Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill. 2014 Mar 6;19(9). Indice Impacto: 5,722. Revista en Q1.
PUBMED DOIY155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors
Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, Molinero M, Lopez-Miragaya I, Rey S, Cañizares A, Rodriguez G, Gonzalez-Velasco C, Lackenby A, Casas I. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro Surveill. 2014 Jul 10;19(27):14-20. Indice Impacto: 5,722. Revista en Q1
PUBMED DOICharacterization In Vitro and In Vivo of a Pandemic H1N1 Influenza Virus from a Fatal Case.
Rodriguez A, Falcon A, Cuevas MT, Pozo F, Guerra S, García-Barreno B, Martinez-Orellana P, Pérez-Breña P, Montoya M, Melero JA, Pizarro M, Ortin J, Casas I, Nieto A. Characterization In Vitro and In Vivo of a Pandemic H1N1 Influenza Virus from a Fatal Case. PLoS One. 2013;8(1):e53515. doi: 10.1371/journal.pone.0053515. Epub 2013 Jan 10. Indice Impacto: 3,534. Revista en Q1
PUBMED DOIMycobacterium tuberculosis genotypes and predominant clones among the multidrug-resistant isolates in Spain 1998-2006
3. Samper S, Gavin P, Millan-Lou MI, Iglesias M.J. Jimenez MS. Spanish Working Group on MDR-TB, Covin D, Rastogi N. Mycobacterium tuberculosis genotypes and predominant clones among the multidrug-resistant isolates in Spain 1998-2006. Infec Genet Evol. 2017. Aug 5;55:117.
PUBMED DOIAntitubercular drugs for an old target: GSK693 as a promising inhA direct inhibitor.
5. Martinez-Hoyos M, Perez-Herran E, Gulten G, Encinas L, Alvarez-Gomez D, Alvarez E, Ferrer Bazaga S, Garcia-Perez A, Ortega F, Angulo-Bartures I, Rullas-Trincado J, Blanco Ruano D, Torres P, Castañeda P, Huss S, Fernandez R, Gonzalez del Valle S, Ballel L, Barros D, Modha S, Dhar N, Signorino-Gelo F, McKinney JD, Garcia-Bustos JF, Lavandera JL, Sacchettini JC, Jimenez MS, Martin-Casabona N, Castro-PIchel J, Mendoza-Losana A. Antitubercular drugs for an old target: GSK693 as a promising inhA direct inhibitor. EBioMedicine. 2016; 8:291-301
PUBMED DOIPediatric drug-resistant tuberculosis in Madrid family matters
7. Santiago B, Baquero-Artiago F, Mejias A, Blázquez D, Jimenez MS, Mellado-Peña MJ, EREMITA Study group. Pediatric drug-resistant tuberculosis in Madrid: family matters. The Pediatric Infectious Disease Journal. 2014; 33:345-350.
PUBMED DOIMycobacterium kumamotonense, another Member of the Mycobacterium terrae Complex Unusually Carrying Two Copies of the Ribosomal RNA Operon
8. Menéndez MC, Jiménez MS, Yubero J, García MJ. Mycobacterium kumamotonense, another Member of the Mycobacterium terrae Complex Unusually Carrying Two Copies of the Ribosomal RNA Operon. Mycobac Dis; 2014; 4:176.
DOIContent with Investigacion .
-

Isabel Jado García
Científico Titular OPIS, Director laboratorio
-
Raquel Escudero Nieto
Científico Titular OPIS, Director laboratorio
-
Escolástica Chaparro Tercero
Técnico de Laboratorio
-
Ave María Vila-Coro Laviña
Auxiliar de Investigación
-
María Elena Andrés Galván
Ayudante de Investigación.
Técnico superior en laboratorio de diagnóstico clínico en 2013 y Técnico superior en laboratorio de análisis y control de calidad en 2015. Lleva vinculada a la Unidad de Neumococos desde 2022 como ayudante de investigación y es personal de plantilla. Anteriormente estuvo contratada en el Instituto de recursos naturales y agrobiología de Salamanca (IRNASA) del CSIC.
List of staff

Additional Information
The group is interested in the study of the immune response from a multidisciplinary perspective that includes genomic, biochemical, proteomic, in vivo and biotechnological models aimed at the design of therapeutic strategies against various chronic, infectious and rare diseases that have a clear immunological component in their etiology.
The current specific objectives focus on:
- Antigenic presentation: Identification of antigenic presentation rules for their application in the design of therapeutic treatments including vaccines.
- Study of CD69 function and its regulation; its use as a therapeutic target in the mobilization of hematopoietic precursors and in the potentiation of the immune response mediated by CD69 with the potentiation of vaccines using the vaccinia virus as a vector.
The group is interested in the study of the immune response from a multidisciplinary perspective that includes genomic, biochemical, proteomic, in vivo and biotechnological models aimed at the design of therapeutic strategies against various chronic, infectious and rare diseases that have a clear immunological component in their etiology.
The current specific objectives focus on:
- Antigenic presentation: Identification of antigenic presentation rules for their application in the design of therapeutic treatments including vaccines.
- Study of CD69 function and its regulation; its use as a therapeutic target in the mobilization of hematopoietic precursors and in the potentiation of the immune response mediated by CD69 with the potentiation of vaccines using the vaccinia virus as a vector.